Paciente trasplantado renal con enfermedad linfoproliferativa post-trasplante (PTLD) tardía y glomerulopatía colapsante del injerto renal

  • Luciano Leguizamón Programa de Trasplante Renal, Hospital de Clínicas José de San Martí, Buenos Aires
  • Pablo Barbero Programa de Trasplante Renal, Hospital de Clínicas José de San Martín, Universidad de Buenos Aires, Buenos Aires
  • Lilian Martinez Programa de Trasplante Renal, Hospital de Clínicas José de San Martín, Universidad de Buenos Aires, Buenos Aires
  • Gerardo Gutiérrez Avilés División Nefrología, Hospital de Clínicas José de San Martín, Universidad de Buenos Aires, Buenos Aires
  • Hernán Sarzuri Marca División Nefrología, Hospital de Clínicas José de San Martín, Universidad de Buenos Aires, Buenos Aires
  • Fernando Segovia División Nefrología, Hospital de Clínicas José de San Martín, Universidad de Buenos Aires, Buenos Aires
  • Laura Idiarte Programa de Trasplante Renal, HHospital de Clínicas José de San Martín, Universidad de Buenos Aires, Buenos Aires

Citas

Allen UD. Clinical features and Diagnosis evaluation of post-transplant lymphoproliferative disease. En: Dharnidharka VR, Green M, Webber SA, eds. Posttransplant

lymphoproliferative disorders. Heidelberg, Springer, 2010; p. 69-88.

Ashrafi F, Shahidi S, Ebrahimi Z, Mortazavi M. Outcome of rapamycin therapy for post-transplant-lymphoproliferative disorder after kidney transplantation: case series. Int J Hematol Oncol Stem Cell Res. 2015;9(1):26-32.

Bakker NA, Pruim J, de Graaf W, van Son WJ, van der Jagt EJ, van Imhoff GW. PTLD visualization by FDG-PET: improved detection of extranodal localizations. Am J Transplant. 2006;6(8):1984-5.

Bowden RA, Ljungman P, Snydman DR, eds. Transplant infections. 3rd ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins, 2010.

Colvin RB. Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. J Am Soc Nephrol. 2007;18(4):1046-56.

Ferreira H, Bustorff M, Santos J, Ferreira I, Sampaio S, Salomé I, et al. Post-transplant Lymphoproliferative Disorder: A Single-Center Experience. Transplant Proc. 2015;47(4):981-4.

Feucht HE. Complement C4d in graft capillaries the missing link in the recognition of humoral alloreactivity. Am J Transplant. 2003;3(6):646-52.

Gupta R, Sharma A, Mahanta PJ, Agarwal SK, Dinda AK. Focal and segmental glomerulosclerosis in renal allograft recipients: a clinico-pathologic study of 37 cases. Saudi J Kidney Dis Transpl. 2013;24(1):8-14.

Halloran PF, Wadgymar A, Ritchie S, Falk J, Solez K, Srinivasa NS. The significance of the anti-class I antibody response. I. Clinical and pathologic features of anti-class I-mediated rejection. Transplantation. 1990;49(1):85-91.

Sureshkumar KK, Dosani I, Jasnosz KM, Arora S. De Novo Collapsing Glomerulopathy: An Unusual Cause of Early Graft Failure following Kidney Transplantation. Case Rep Transplant. 2001;2001: 263970.

Kasiske BL, Kukla A, Thomas D, Wood Ives J, Snyder JJ, Qiu Y, et al. Lymphoproliferative disorders after adult kidney transplant: epidemiology and comparison of registry report with claims-based diagnoses. Am J Kidney Dis. 2011;58(6):971-80.

Letavernier E, Bruneval P, Mandet C, Duong Van Huyen JP, Péraldi MN, Helal I, et al. High sirolimus levels may induce focal segmental glomerulosclerosis de novo. Clin J Am Soc Nephrol. 2007;2(2):326-33.

Meehan SM, Pascual M, Williams WW, Tolkoff-Rubin N, Delmonico FL, et al. De novo collapsing glomerulopathy in renal allografts. Transplantation. 1998;65(9):1192-7.

Mohamed N, Goldstein J, Schiff J, John R. Collapsing glomerulopathy following anthracycline therapy. Am J Kidney Dis. 2013;61(5):778-81.

Mubarak M. Collapsing focal segmental glomerulosclerosis: Increasing the awareness. J Nephropathol. 2012;1(2):77-80.

Mucha K, Foroncewicz B, Ziarkiewicz-Wróblewska B, Krawczyk M, Lerut J, Paczek L. Post-transplant lymphoproliferative disorder in view of the new WHO classification: a more rational approach to a protean disease? Nephrol Dial Transplant. 2010;25(7):2089-98.

Serre JE, Michonneau D, Bachy E, Noël LH, Dubo V, Suberbielle C, et al. Maintaining calcineurin inhibition after the diagnosis of post-transplant lymphoproliferative disorder improves renal graft survival. Kidney Int. 2014;85(1):182-90.

Steven H. Swerdlow. Pathology. En: VR Dharnidharka, M Green, SA Webber, eds. Post-transplant lymphoproliferative disorders. Heidelberg, Springer, 2010; p. 89-104.

Stokes MB, Davis CL, Alpers CE. Collapsing glomerulopathy in renal allografts: a morphological pattern with diverse clinicopathologic associations. Am J Kidney Dis. 1999;33(4):658-66.

Tsai DE, Hardy CL, Tomaszewski JE, Kotloff RM, Oltoff KM, Somer BG, et al. Reduction in immunosuppression as initial therapy for posttransplant lymphopro-liferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation. 2001;71(8):1076-88.

Terasaki PI, Ozawa M, Castro R. Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am J Transplant. 2007;7(2):408-15.

Trpkov K, Campbell P, Pazderka F, Cockfield S, Solez K, Halloran PF. Pathologic features of acute renal allograft rejection associated with donor-specific antibody, Analysis using the Banff grading schema. Transplantation. 1996;61(11):1586-92.

Zou Y, Stastny P, Süsal C, Döhler B, Opelz G. Antibodies against MICA antigens and kidney-transplant rejection. N Engl J Med. 2007;357(13):1293-300.

Publicado
2016-03-15
Cómo citar
1.
Leguizamón L, Barbero P, Martinez L, Gutiérrez Avilés G, Sarzuri Marca H, Segovia F, Idiarte L. Paciente trasplantado renal con enfermedad linfoproliferativa post-trasplante (PTLD) tardía y glomerulopatía colapsante del injerto renal. Rev Nefrol Dial Traspl. [Internet]. 15 de marzo de 2016 [citado 20 de abril de 2024];36(1):54-1. Disponible en: http://www.revistarenal.org.ar/index.php/rndt/article/view/55
Número
Vol. 36 Núm. 1 (2016): Ene.-Mar.
Sección
Casuística